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Background: The efﬁcacy of epinastine 0.05% ophthalmic solution for pollen allergic conjunctivitis has
already been shown in a conjunctival allergen challenge (CAC) test using cedar pollen as a challenge. The
present study investigated the efﬁcacy of this solution against birch pollen conjunctivitis in a CAC test.
Methods: Ten adult subjects (eight males and two females) with asymptomatic birch pollen conjuncti-
vitis were enrolled in this study. The average age of the subjects was 41.1 years. This study was conducted
during a period without birch pollen dispersion. In each subject, the epinastine 0.05% ophthalmic so-
lution was instilled in one eye, and an artiﬁcial tear ﬂuid was instilled in the fellow eye in a double-blind
manner. Five minutes or 4 h after the drug instillation, both eyes were challenged with an optimal
concentration of birch pollen, and ocular itching and conjunctival hyperemia were then graded. Tears
were collected before the drug instillation and 20 min after the pollen challenge, and the histamine level
was measured.
Results: The ocular itching scores and palpebral conjunctival hyperemia scores of the epinastine-treated
eyes were signiﬁcantly lower than those of the contralateral control eyes when the eyes were pretreated
with the drug 4 h before the CAC. There was a signiﬁcant correlation between the tear histamine level
and mean ocular itching score of three time points (3, 5 and 10 min) following the CAC in the control eyes
but not the epinastine-treated eyes.
Conclusions: Epinastine is effective in suppressing ocular itching and conjunctival hyperemia in birch
pollen conjunctivitis.
Copyright © 2016, Japanese Society of Allergology. Production and hosting by Elsevier B.V. This is an open access
article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).Introduction
Allergic conjunctivitis is a conjunctival inﬂammatory disease
associated with a type 1 allergy.1 It is classiﬁed as seasonal allergic
conjunctivitis (SAC) and perennial allergic conjunctivitis. Various
species of pollen can be causative antigens of SAC, and variation of
pollen depends on the region and season. Cedar pollen is the most
common antigen for SAC in Japan, except for Hokkaido prefecture
in the north of Japan. In Hokkaido, birch pollen is themost common
antigen of SAC,2 and the birch pollen-related SAC season lastsology, Hokkaido University
, Sapporo 060-8638, Japan.
mba).
ety of Allergology.
rgology. Production and hosting by Else
, et al., Evaluating the efﬁca
pollen allergic conjunctialmost one month, from the end of April to the beginning of June.
Birch pollen is also a major allergen trigger in the spring in Europe
and North America.3
Eye drops containing antiallergic ophthalmic solutions are
the main treatment for allergic conjunctivitis. Epinastine has
both effects of antihistamine properties, blocking the histamine
1 (H1) receptor,4 and chemical mediator stabilizer properties,
inhibiting the release of mediators, including histamine and
leukotrienes.5,6 A phase III study demonstrated that epinastine
0.05% ophthalmic solution was effective in suppressing SAC
symptoms in patients in a conjunctival allergen challenge (CAC)
test using an allergen solution of cedar pollen.7 To our knowl-
edge, the efﬁcacy of epinastine 0.05% ophthalmic solution in
treating SAC caused by other antigens has not been studied. In
this study, its efﬁcacy was examined in a CAC test using birch
pollen in humans.vier B.V. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/
cy of epinastine ophthalmic solution using a conjunctivitis allergen
vitis, Allergology International (2016), http://dx.doi.org/10.1016/
Table 1






3: Continuous itching with the desire to rub, normal functioning not
impaired
4: Incapacitating (impairs subject's normal functioning)
Palpebral and bulbar conjunctival hyperemia
0: None
1: Dilation of a few blood vessels in part of the palpebral/bulbar conjunctiva
2: Dilation of many blood vessels in the entire palpebral/bulbar conjunctiva
3: Redness of entire palpebral/bulbar conjunctiva/individual blood vessels
cannot be distinguished
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Subjects
Thirty-six healthy adult volunteers with a history of birch pollen
allergic conjunctivitis and no ocular symptoms were selected from
December 2014 to February 2015 (outside the birch pollen season).
The study was approved by the ethics committee of Hokkaido
University Hospital (approval number 014-0193) and carried out in
accordance with the Declaration of Helsinki and Ethical Guideline
for Clinical Studies stipulated by the Ministry of Health, Labor and
Welfare, Japan. All the patients who participated in this study
provided written consent after they received oral and written in-
formation about the study. The study was registered at https://
center.umin.ac.jp with the ID code UMIN000015797.
This was a prospective, double-masked, randomized, placebo-
controlled, single-center (Hokkaido University Hospital, Hok-
kaido, Japan) study.
Allergen solution
An allergen solution was prepared from glycerol 1:20 w/v birch
pollen extract solution (Birch Mix PRW HollisterStier, Spokane,
WA). Before the challenge tests, the extract was diluted with a
diluent of chondroitin sulfate 1:100 w/v, NaCl 2:10,000 w/v andFig. 1. Outline of this study. CAC, conjunctivitis allergen challenge; EPI/AT, epinastine hydr
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j.alit.2016.08.011glycerol 2:100 w/v. Diluted allergen solution was prepared at
different concentrations (25-fold, 50-fold, 100-fold, and 200-fold).
CAC
The clinical methodology and grading system for allergic
conjunctivitis followed those reported earlier.7,8 The optimal con-
centration of the allergen solution was determined individually at
the second visit. The allergen solution was instilled into the sub-
ject's eye, and the severity of ocular itching and palpebral and
bulbar conjunctival hyperemia was evaluated according to the
previous study.7 Table 1 shows the grading of ocular allergic
symptoms (ocular itching and conjunctival hyperemia).
Clinical trial design
Figure 1 shows the outline of this study. For the duration of the
study, the subjects were instructed not to use corticosteroids,
antiallergic drugs, immune suppressants, or immunomodulation
therapy, topically nor systemically, and subjects who experienced
ocular allergic symptoms including ocular itching and conjunctival
hyperemia before the CAC were excluded.
At visit 1, after written informed consent was obtained, subjects
were excluded according to demographic data such as age (20>,
65<) and pregnancy. Subjects who had a negative response to
serum birch pollen-speciﬁc Immunoglobulin E (IgE) in a capsulated
hydrophilic carrier polymer radioallergosorbent test were excluded
from the study.
At visit 2, CAC tests were performed according to the previous
study.7 After the allergen control solution (Allergen Scratch Extract
Torii Control Solution, Torii Pharmaceutical, Tokyo, Japan) was
instilled into the conjunctiva to exclude subjects who showed a
conjunctival inﬂammatory reaction to the allergen solutionwithout
pollen antigen, 30 mL of the lowest allergen solution was instilled
into each eye. The allergen concentration was increased until an
ocular itching score of at least 2 (continuous itching) was recorded
and both palpebral and bulbar conjunctival hyperemia scores of at
least 1 (dilation of a few blood vessels) were elicited bilaterally
within 10 min. The lowest concentration that produced these
symptoms in each subject was the optimal concentration of
allergen solution in the CAC. Subjects who failed to show sufﬁcientochloride ophthalmic solution 0.05% in one eye/artiﬁcial tear in the contralateral eye.
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highest concentration of the allergen solution, were excluded from
this study.
At visit 3, the CAC was performed again, using the optimal
concentration of the allergen solution determined at visit 2 to
ascertain the reproducibility of the CAC with the allergen solution.
After visits 2 and visit 3, 11 subjects left the study. The remaining 10
subjects were included in the randomized arm of the study at visits
4 and 5.
At visit 4, the subjects were randomly assigned to receive epi-
nastine (ALESION ophthalmic solution 0.05%, Santen Pharmaceu-
tical, Osaka, Japan, epinastine hydrochloride ophthalmic solution)
in one eye and an artiﬁcial tear solution (Soft Santear, Santen
Pharmaceutical, Osaka, Japan) in the contralateral eye. An assistant
covered the labels on the study drugs to mask their identity. The
technician who instilled a drop of the study medication into each
eye was not involved in any other aspect of the study. Five minutes
after the drug instillation, the CACwas performed using the optimal
antigen concentration (50-fold dilution [n ¼ 2], 100-fold dilution
[n ¼ 2], and 200-fold dilution [n ¼ 6]), and ocular itching and
palpebral and bulbar conjunctival hyperemia were evaluated.
At visit 5, 4 h after the drug instillation, the CAC was performed,
and the same ocular allergy symptoms were evaluated.
Tear histamine levels
Tears were collected using a paper Schirmer strip (Color Bar
Schirmer, EagleVision, Memphis, TN, USA) before the CAC and
20 min after the challenge at visit 4. The strips were placed in the
edge of the lower eyelid for 5 min in the same manner as in a
Schirmer I test. The histamine level in the collected tear was
measured using commercially available an enzyme-linked immu-
nosorbent assay.9,10
Statistical analysis
The target sample size was determined to be 10 subjects,
presuming that the difference in ocular itching following the two
treatments (test and artiﬁcial tear solutions) was 1.4, with an SD of
0.9 in a paired t-test (two-tailed, signiﬁcance level 5%, power 80%).Fig. 2. Flowchart of s
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time points (3, 5 and 10 min) following the CAC 4 h after the drug
instillation. Statistical analyses were performedwith a paired t-test.
For all tests, a probability value of less than 0.05 was considered
statistically signiﬁcant.Results
Characteristics of the subjects
Of the 36 subjects who gave written consent, 10 subjects (two
females and eight males, with a mean [SD] age of 41.1 [8.3] years)
were included in a randomized trial at visit 4 and visit 5. The ma-
jority of the subject exclusions were due to negative birch pollen-
speciﬁc serum IgE (n ¼ 12) or an insufﬁcient allergic reaction at
either visit 2 or visit 3 (n ¼ 9) (Fig. 2).Efﬁcacy of the drug pretreatment 5 min before the CAC
At visit 4, the CAC was performed 5 min after the drug treat-
ment. Themean (SD) ocular itching scores 3 min, 5 min, and 10min
after the CAC were 1.8 (1.2), 1.8 (1.3), and 1.6 (1.1) in the epinastine-
treated eyes and 2.5 (1.0), 2.3 (0.7), 2.2 (0.9) in the control eyes,
respectively. The ocular itching score of the epinastine-treated eyes
10min after the CACwas signiﬁcantly lower than that of the control
eyes (P ¼ 0.024, Fig. 3A).
The palpebral conjunctival hyperemia scores of the epinastine-
treated eyes were also signiﬁcantly lower than those of the con-
trol eyes 10 min after the CAC (P ¼ 0.037, Fig. 4A).Efﬁcacy of drug pretreatment 4 h before the CAC
At visit 5, the CAC was performed 4 h after the drug treatment.
The mean (SD) ocular itching scores 3 min, 5 min, and 10 min after
the CAC were 0.8 (0.9), 1.0 (0.8), and 0.7 (0.8) in the epinastine-
treated eyes and 1.5 (1.2), 1.5 (0.8), 1.6 (1.0) in the control eyes,
respectively. The ocular itching scores in the epinastine-treated
eyes 3 min and 10 min after the CAC were signiﬁcantly lower
than those of the control eyes (P ¼ 0.025, 0.010, Fig. 3B).tudy population.
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Fig. 4. Time-course change in the mean palpebral conjunctival hyperemia scores after the allergen challenge. A: 5 min after the drug instillation, B: 4 h after the drug instillation
(n ¼ 10 subjects, mean ± SD, *P < 0.05).
Fig. 3. Time-course change in the mean ocular itching scores after the allergen challenge. A: 5 min after the drug instillation, B: 4 h after the drug instillation (n ¼ 10 subjects,
mean ± SD, *P < 0.05).
Y. Tagawa et al. / Allergology International xxx (2016) 1e64The mean palpebral conjunctival hyperemia scores were also
signiﬁcantly lower in the epinastine-treated eyes than in the con-
trol eyes 10 and 20 min after the CAC (P ¼ 0.045, 0.037, Fig. 4B).
Furthermore, both the mean ocular itching and the mean
palpebral conjunctival hyperemia scores of the three time points
(ocular itching at 3, 5 and 10 min, conjunctival hyperemia at 5, 10
and 20 min) of the epinastine-treated eyes were signiﬁcantly lower
than those of the control eyeswhen theywere pretreated 4 h before
(P¼ 0.017, 0.038, Table 2). No signiﬁcant differencewas foundwhen
they were pretreated 5 min before the CAC.
Tear histamine levels
The histamine concentration in the tears was examined before
the drug pretreatment and 20 min after the CAC. In 16 eyes (80%),
post-CAC histamine levels were elevated compared to the pre-
treatment levels. However, the pretreatment mean tear histamineTable 2
Mean ocular itching score and conjunctival hyperemia of the three time points after the









2.3 ± 0.8 1.8 ± 0.7 2.0 ± 0.7
Epinastine 1.7 ± 1.2 1.6 ± 0.7 1.7 ± 0.6
*P < 0.05.
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(Fig. 5). Furthermore, there was a positive correlation between the
tear histamine level and the mean of ocular itching score of three
time points (3, 5 and 10 min) following the CAC in the control eyes
(r2 ¼ 0.5002, P ¼ 0.022, Fig. 6A), whereas no such correlation was
found in the epinastine-treated eyes (Fig. 6B). Similarly, there was
also a positive correlation between the tear histamine level and the
mean of palpebral conjunctival hyperemia score of three time
points (5, 10 and 20 min) following the CAC in the control eyes
(r2 ¼ 0.4579, P ¼ 0.032, Fig. 7A).Discussion
The CAC was developed by Abelson MB et al. initially,11,12 and
then, both American Food and Drug Administration and Japanese
Pharmaceuticals and Medical Devices Agency recognize the use ofallergen challenge.







1.5 ± 0.8 1.3 ± 0.7 1.4 ± 0.8
0.8 ± 0.8* 0.7 ± 0.4* 0.8 ± 0.7
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Fig. 5. Tear histamine level before drug instillation and 20 min after the allergen challenge at 5 min after the drug instillation. A: Artiﬁcial tear-treated eyes, B: Epinastine-treated
eyes (n ¼ 10 subjects, mean ± SD).
Fig. 6. The relationship between the tear histamine level and mean ocular itching score of the three time points after the allergen challenge. A: Artiﬁcial tear-treated eyes, B:
Epinastine-treated eyes (n ¼ 10 subjects).
Fig. 7. The relationship between the tear histamine level and mean palpebral conjunctival hyperemia of the three time points after the allergen challenge. A: Artiﬁcial tear-treated
eyes, B: Epinastine-treated eyes (n ¼ 10 subjects).
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ophthalmic solutions.
In Japan, thus far, only cedar pollen has been used in the CAC
test.13,14 In the present study, birch pollenwas used as an antigen. ToPlease cite this article in press as: Tagawa Y, et al., Evaluating the efﬁca
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population is prone to birch pollen allergy,3 and the allergy is
considered a social problem. Peoplewith birch pollen allergy present
with asthma, rhinitis and conjunctivitis.
Birch pollen can also induce oral allergy syndrome (OAS).16
Some people with birch pollen allergy are also allergic to various
fruits, such as apples, peaches, and cherries. OAS is considered to be
due to a cross-immune reaction caused by molecular mimicry.17
OAS is a major issue not only in Hokkaido, Japan but also in other
countries, such as Sweden and Finland. The prevalence of OAS
highlights the need for birch pollen allergy studies.
Epinastine ophthalmic solution is commercially available and its
efﬁcacywas demonstrated in a phase III study inwhich cedar pollen
was used in the CAC test.7WeperformedCAC test using almost same
protocol as the previous phase III study, and differences were 1) the
challenging antigen, i.e., ‘cedar’ pollen in the previous study and
‘birch’ pollen in our current study, and 2) the period from the drug
instillation to antigen challenge, i.e., ‘15 min’ in the previous study
and ‘5 min’ in this study. In the present study, as well, epinastine
ophthalmic solution was effective in suppressing allergic conjunc-
tivitis inducedbybirchpollen. Earlier studies reported the efﬁcacyof
epinastinewhen it was administered 15min prior to the instillation
of an antigen.7,18 In this study, the epinastine ophthalmic solution
was applied 5min prior to the antigen challenge to assess the rapid-
acting efﬁcacy of the solution. The results revealed that it had
moderate effectiveness and that its effectiveness reduced compared
with the solution which was administered 4 h prior to the antigen
challenge. Thus, epinastine ophthalmic solution can be considered
to have mild rapid-acting efﬁcacy.
A previous study reported that the histamine concentration in
tear ﬂuid was elevated in a CAC test.10 In the present study, the
histamine concentration increased in 80% of subjects after the
allergen challenge, and the histamine concentration in the tear
ﬂuid was positively correlated with the ocular itching score in the
control group. On the other hand, therewas no correlation between
the histamine concentration in the tear ﬂuid and the ocular itching
score in the epinastine group. Epinastine has the potential to block
the H1 receptor. The absence of a correlation between the hista-
mine concentration and ocular itching score may be due to the H1
receptor blocking action of epinastine, with the solution sup-
pressing ocular itching, even in the presence of a high concentra-
tion of histamine in the tears. A previous study also reported that
the histamine concentration in tear ﬂuid was correlated with the
severity of allergic symptoms in control eyes, whereas it was not
correlated with the severity of symptoms in eyes treated with
antihistamine ophthalmic solutions.19 Although the study was
seasonal observation study but not provocation study, the results of
that study correspond to those of the present work.
In the current study, the pretreatment with epinastine
ophthalmic solution had no effect on the histamine concentration
in the tear ﬂuid after the allergen challenge. In an earlier study,
when patients were premedicated for 5 days with an antihistamine
ophthalmic solution, a lower tear histamine level was observed
after an allergen challenge.10 In the present study, the eyes were
premedicated only once with a drop of epinastine ophthalmic so-
lution 5 min or 4 h before the allergen challenge. To determine the
potential of an ophthalmic solution to suppress the release of his-
tamine (i.e., degranulation of mast cells), a longer period of pre-
medication with the ophthalmic solution would be required.
Epinastine is also known to act as an inverse agonist and to
down-regulate the gene expression activity of the H1 receptor.20,21
This study involved a single premedication with epinastine
ophthalmic solution. If the eyes were premedicated with the so-
lution for longer periods, it would likely have shown a greater
ability to suppress ocular symptoms.Please cite this article in press as: Tagawa Y, et al., Evaluating the efﬁca
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